- Stocks
- Pharma & Healthcare
- Parnax Lab
Parnax Lab share price
NSE: PARNAXLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Parnax Lab at a glance
Parnax Lab (NSE: PARNAXLAB) closed at ₹104.00 on 21 Oct 2026. With a market capitalisation of ₹119 Cr, it ranks 2568th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 10.1× trailing earnings, against a return on equity of 12.4% in FY26. Its 52-week range is ₹102.00 (21 Oct 2026) to ₹149.50 (10 Sep 2026); the last close is 30.4% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹70 Cr (+42.0% year on year) and net profit ₹2 Cr (−25.6%), on a consolidated basis. Promoters held 72.30% of the company as of 30 Jun 2026; 9.41% of promoter shares were pledged.
Key numbers
- Market cap
- ₹119 CrRank 2568 on NSE
- P/E (trailing)
- 10.1×
- Price to book
- 1.55×FY26
- EPS (TTM)
- ₹10.27to Q4 FY26
- ROE
- 12.4%FY26
- ROCE
- 17.4%FY26
- Debt to equity
- 0.78FY26
- Net profit margin
- 4.7%FY26
- Book value / share
- ₹82.83FY26
- 52-week high
- ₹149.5010 Sep 2026
- 52-week low
- ₹102.0021 Oct 2026
- RSI (14-day)
- 38
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −4.54% | −8.6% | −19.4% | — | — |
Parnax Lab quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹50 Cr | ₹48 Cr | ₹40 Cr | ₹49 Cr | ₹53 Cr | ₹63 Cr | ₹63 Cr | ₹70 Cr |
| Revenue YoY | +2.8% | +13.5% | −21.1% | +5.8% | +6.5% | +29.4% | +56.5% | +42.0% |
| Net profit | ₹4 Cr | ₹3 Cr | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr |
| Net profit YoY | +19.8% | +82.4% | −44.5% | +30.2% | −18.0% | +6.2% | +124.8% | −25.6% |
| Net margin | 8.0% | 7.1% | 3.0% | 6.0% | 6.1% | 5.8% | 4.3% | 3.1% |
| EPS | ₹3.47 | ₹2.97 | ₹1.06 | ₹2.55 | ₹2.85 | ₹3.15 | ₹2.37 | ₹1.90 |
Parnax Lab financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹90 Cr | ₹163 Cr | ₹168 Cr | ₹189 Cr | ₹188 Cr | — |
| Operating profit | −₹0 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹16 Cr | — |
| Net profit | −₹0 Cr | ₹8 Cr | ₹9 Cr | ₹10 Cr | ₹12 Cr | — |
| EPS (₹) | ₹0.00 | ₹10.00 | ₹8.00 | ₹8.00 | ₹10.00 | — |
| Cash from operations | ₹6 Cr | ₹9 Cr | ₹21 Cr | ₹16 Cr | ₹32 Cr | — |
| Total debt | ₹14 Cr | ₹17 Cr | ₹12 Cr | ₹21 Cr | ₹18 Cr | ₹22 Cr |
| Shareholders' equity | ₹33 Cr | ₹48 Cr | ₹62 Cr | ₹72 Cr | ₹83 Cr | ₹95 Cr |
Parnax Lab shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% | 72.30% |
| Non-institutions | 27.70% | 27.70% | 27.70% | 27.70% | 27.70% | 27.70% |
| Promoter shares pledged | 9.41% | 9.41% | 9.41% | 9.41% | 9.41% | 9.41% |
Parnax Lab vs peers
The listed Pharma & Healthcare companies nearest to Parnax Lab by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ASPIRAAspira Pathlab | — | — | — | ₹125 Cr | — | — |
| KREBSBIOKrebs Biochemicals and Industries | ₹56.59 | +0.78% | −19.3% | ₹122 Cr | — | — |
| GODAVARIGodavari Drugs | — | — | — | ₹120 Cr | — | — |
| PARNAXLABParnax Lab | ₹104.00 | −4.54% | — | ₹119 Cr | 10.1 | — |
| MAKERSLMakers Labs | ₹191.02 | −3.53% | — | ₹113 Cr | 48 | — |
| PHARMAIDPharmaids Pharm | — | — | — | ₹113 Cr | — | — |
| BALAXIBALAXI PHARMACEUTICALS | ₹20.31 | −4.65% | −52.7% | ₹112 Cr | 78.1 | — |
Ask anything about Parnax Lab
Pivot answers on the live chart with evidence you can check, and tests strategies against PARNAXLAB's own history. Try: “Why has PARNAXLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on PARNAXLAB over five years” · “Compare PARNAXLAB with ASPIRA on margins and valuation”
Frequently asked questions about Parnax Lab
What is the share price of Parnax Lab today?
Parnax Lab (NSE: PARNAXLAB) last closed at ₹104.00 on 21 Oct 2026. Its 52-week high is ₹149.50 and its 52-week low is ₹102.00.
What is the market cap of Parnax Lab?
Parnax Lab's market capitalisation is ₹119 Cr (₹119 Cr) at the 22 Oct 2026 close, ranking 2568th among the NSE companies Pivot tracks.
What is the P/E ratio of Parnax Lab?
Parnax Lab trades at a trailing P/E of 10.1.
What is the ROE and ROCE of Parnax Lab?
Return on equity was 12.4% in FY26 and return on capital employed was 17.4% in FY26 (consolidated figures).
Is Parnax Lab a debt-free company?
No. Parnax Lab's debt-to-equity ratio was 0.78 in FY26, with total debt of ₹22 Cr.
What were Parnax Lab's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Parnax Lab reported revenue of ₹70 Cr, +42.0% year on year, and net profit of ₹2 Cr, −25.6% year on year.
What is the shareholding pattern of Parnax Lab?
As of 30 Jun 2026: promoters 72.30%, non-institutions 27.70%. 9.41% of promoter shares were pledged.
Who are Parnax Lab's competitors?
The listed Pharma & Healthcare companies closest to Parnax Lab by market cap are Aspira Pathlab, Krebs Biochemicals and Industries, Godavari Drugs, Makers Labs, Pharmaids Pharm and BALAXI PHARMACEUTICALS.
Is Parnax Lab a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Parnax Lab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PARNAXLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text